Erlocip 150 Tablet
Marketer
Cipla Ltd
Salt Composition
Erlotinib (150mg)
Overview Erlocip 150 Tablet
Erlocip 150mg tablets treat non-small cell lung and pancreatic cancers. Administer this medication on an empty stomach, or one hour before or two hours after eating. Continue treatment as directed by your physician; its duration depends on individual response. Follow your doctor's instructions precisely; incorrect usage or overdosage can lead to serious adverse effects. Benefits may take weeks or months to appear; discontinue only under your doctor's guidance. Common side effects include nausea, vomiting, tiredness, skin rash, and weight loss. Severe diarrhea requires increased fluid intake or medical attention. Photosensitivity is possible; wear protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Your doctor may order regular liver function tests. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medicine is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners. Smoking cessation is recommended during treatment. If using antacids or other medications, maintain a two-hour interval between doses.
Primary Ingredients of Erlocip 150 Tablet
No text provided. Please provide the text you want me to rephrase.
Uses of Erlocip 150 Tablet
Cancers of the pancreas and non-small cell lung
Major Benefits of Erlocip 150 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Erlocip 150 Tablet on an empty stomach.
Common Side effects of Erlocip 150 Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erlocip 150 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Administer Erlocip 150 Tablet on an empty stomach.
How Erlocip 150 Tablet works:
Erlocip 150mg tablets are an anti-neoplastic agent. Lung cancer cells utilize epidermal growth factor receptors (EGFR) on their surface to regulate proliferation. This drug functions by attaching to and blocking EGFR, thereby disrupting the cancer's EGFR-dependent signaling and subsequently limiting tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The safety of alcohol consumption while taking Erlocip 150 Tablet is undetermined. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Erlocip 150 Tablet during pregnancy poses a confirmed risk to the fetus. Its use should be avoided except in exceptional, life-threatening circumstances where the potential benefits outweigh the known dangers, as determined by a physician. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Erlocip 150 Tablet while breastfeeding is likely inadvisable. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Erlocip 150 Tablet on driving ability is undetermined. Refrain from driving if you develop symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Erlocip 150 Tablets are considered safe for individuals with kidney impairment; no dosage modification is necessary. However, its use is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Erlocip 150 mg tablets. Dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Erlocip 150 Tablet :
Omit any missed Erlocip 150 Tablet dose and resume your regular medication regimen. Avoid taking a double dose.
Facts to Know About Erlocip 150 Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |





